What is it about?
This noninvasive (no contrast injections) MRI technique determines how well blood gets in and out of the brain. In Alzheimer disease we found that fluid was slow to get into affected regions of the brain and because of brain leakiness and damage to the drainage system was then trapped in those areas. We refer to this as delayed glymphatic clearance. This development preceded thinking and memory problems that later arise as a result.
Featured Image
Why is it important?
It is clear from the monoclonal antibody treatments for beta amyloid that early treatment of Alzheimer disease is essential. This noninvasive, cost and time efficient (20 min or less) method for identifying early disease, may allow for safe and repetitive screening and follow up of patients, and effective treatments are developed.
Perspectives
This clinical investigation and subsequent write up was started and completed during the covid epidemic limiting the study size. It was a great learning opportunity for all the students and faculty involved, myself included.
Associate Professor of Neurology Charles Joseph
Liberty University College of Osteopathic Medicine
Read the Original
This page is a summary of: Utilizing Reduced Labeled Proton Clearance to Identify Preclinical Alzheimer Disease with 3D ASL MRI, Case Reports in Neurology, May 2023, Karger Publishers,
DOI: 10.1159/000530980.
You can read the full text:
Contributors
The following have contributed to this page
